The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Bayer; Sanofi
Speakers' Bureau - Amgen; Bayer; Sanofi
Genomic landscape of ERBB2/3 alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype.
 
Jeanne Tie
Honoraria - Inivata; SERVIER
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Haystack Oncology; Inivata; MSD Oncology; Pierre Fabre
 
Sherif Mohamed El-Refai
Employment - Tempus
Stock and Other Ownership Interests - Tempus
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CheckmAb; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Sara Lonardi
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Lilly; Merck Serono; MSD; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Andrea Sartore-Bianchi
No Relationships to Disclose
 
Yoshiaki Nakamura
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takao Fujisawa
No Relationships to Disclose
 
Sheau Wen Lok
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Receive annual royalties from my institution (Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia) for sale of patent for venetoclax
 
Hui-Li Wong
No Relationships to Disclose
 
Kunal C. Kadakia
No Relationships to Disclose
 
Elizabeth Mauer
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Research Funding - Tempus
Travel, Accommodations, Expenses - Tempus
 
Mohamed E. Salem
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Taiho Pharmaceutical
Speakers' Bureau - Genentech/Roche; Taiho Pharmaceutical